<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="41823"><DrugName>TH-0318</DrugName><DrugSynonyms><Name><Value>TH-0318</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ThGLP-1, Theratechnologies</Value></Name><Name><Value>LAP-stabilized GLP-1 analogs (diabetes), Theratechnologies/OctoPlus</Value></Name></DrugSynonyms><CompanyOriginator id="22170">Theratechnologies Inc</CompanyOriginator><CompaniesSecondary><Company id="22170">Theratechnologies Inc</Company><Company id="24798">Dr Reddy’s Research and Development BV</Company></CompaniesSecondary><CrossReferences><SourceEntity id="41823" type="Drug"><TargetEntity id="367448" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="22170" type="Company"><TargetEntity id="4295861528" type="organizationId">Theratechnologies Inc</TargetEntity></SourceEntity><SourceEntity id="24798" type="Company"><TargetEntity id="4295884953" type="organizationId">Dr Reddy s Research and Development BV</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3246" type="Action"><TargetEntity id="604" type="Mechanism">Insulin-Releasing Agents</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="2585" type="Action"><TargetEntity id="1216" type="Mechanism">GLP-1 Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00815" type="ciTarget"><TargetEntity id="61549990027403" type="siTarget">Glucagon-like peptide 1 receptor</TargetEntity><TargetEntity id="6273" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="2585">Glucagon-like peptide 1 receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="3246">Insulin release stimulator</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><LastModificationDate>2017-08-29T08:37:31.000Z</LastModificationDate><ChangeDateLast>2009-04-09T14:01:17.000Z</ChangeDateLast><AddedDate>2002-09-26T16:19:16.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22170" linkType="Company"&gt;Theratechnologies&lt;/ulink&gt; was developing TH-0318, a sc formulation of the original  the lead in a series of glucagon-like peptide-1 (GLP-1) analogs stabilized using Theratechnologies' long acting peptide (LAP) technology, for the potential treatment of type 2 diabetes. In October 2004, a phase I trial of TH-0318 was initiated by Theratechnologies [&lt;ulink linkID="564450" linkType="Reference"&gt;564450&lt;/ulink&gt;]. By March 2005, Theratechnologies had formed an advisory panel  to discuss its next steps with the drug  [&lt;ulink linkID="591434" linkType="Reference"&gt;591434&lt;/ulink&gt;]; by May 2007, TH-0318 no longer appeared on the company's pipeline and Theratechnologies was  seeking to outlicense it [&lt;ulink linkID="800181" linkType="Reference"&gt;800181&lt;/ulink&gt;]. In September 2007,  &lt;ulink linkID="24798" linkType="Company"&gt;OctoPlus&lt;/ulink&gt; acquired this series from the company [&lt;ulink linkID="833820" linkType="Reference"&gt;833820&lt;/ulink&gt;]; however, in February 2008, the company decided to take &lt;ulink linkID="61307" linkType="Drug"&gt;OP-286 CR&lt;/ulink&gt; into clinical development, at that time, it was assumed that development of  TH-0318 had been discontinued [&lt;ulink linkID="878889" linkType="Reference"&gt;878889&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="24798" linkType="Company"&gt;&lt;/ulink&gt;Theratechnologies, in collaboration with &lt;ulink linkID="14095" linkType="Company"&gt;ALZA&lt;/ulink&gt;, was also investigating a &lt;ulink linkID="53010" linkType="Drug"&gt;transdermal patch formulation&lt;/ulink&gt;  for type 2 diabetes.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In October 2004, Theratechnologies launched a two-part, phase I trial to assess the tolerability and safety of TH-0318 in both healthy subjects and diabetic patients [&lt;ulink linkID="564450" linkType="Reference"&gt;564450&lt;/ulink&gt;]. In March 2005, results from the  randomized, single-center, dose-escalation, parallel, placebo-controlled trial in 36 healthy male volunteers showed that the safety profile of the treated population was similar to placebo and no cases of nausea, a common side effect of GLP-1 therapy, were observed. At the higher doses tested, decreased blood glucose levels were also observed [&lt;ulink linkID="591434" linkType="Reference"&gt;591434&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt; In September 2002, Theratechnologies expected to select a GLP-1 analog for development during 2003 [&lt;ulink linkID="465091" linkType="reference"&gt;465091&lt;/ulink&gt;]. A lead analog, TH-0318, had been selected by July 2003 [&lt;ulink linkID="497062" linkType="reference"&gt;497062&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2007, OctoPlus acquired the exclusive worldwide development and commercialization rights to a glucagon-like peptide-1 series, including TH-0318, from Theratechnologies, who received an upfront payment and would be entitled to a maximum of EUR 36 million (US $48.54 million) in milestones plus royalties. OctoPlus was responsible for future development costs. At that time, OctoPlus had initiated preclinical development [&lt;ulink linkID="833820" linkType="Reference"&gt;833820&lt;/ulink&gt;], [&lt;ulink linkID="834019" linkType="Reference"&gt;834019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Theratechnologies's LAP technology adds a hydrophobic chain to peptides to slow enzymatic degradation and increase half-life. The LAP-stabilized GLP-1 analogs preserve the natural sequence of the peptide, which the company expected would provide a safety advantage [&lt;ulink linkID="465091" linkType="reference"&gt;465091&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24798">Dr Reddy’s Research and Development BV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2008-02-21T00:00:00.000Z</StatusDate><Source id="878889" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22170">Theratechnologies Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2007-09-26T00:00:00.000Z</StatusDate><Source id="833820" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22170">Theratechnologies Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2002-09-26T00:00:00.000Z</StatusDate><Source id="465091" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22170">Theratechnologies Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2004-10-12T00:00:00.000Z</StatusDate><Source id="564450" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22170">Theratechnologies Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2007-05-30T00:00:00.000Z</StatusDate><Source id="800181" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24798">Dr Reddy’s Research and Development BV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2007-09-26T00:00:00.000Z</StatusDate><Source id="833820" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00815"><Name>Glucagon-like peptide 1 receptor</Name><SwissprotNumbers><Swissprot>O35659</Swissprot><Swissprot>P32301</Swissprot><Swissprot>P43220</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="22170">Theratechnologies Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29387">Dr Reddy's Laboratories Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="110302" title="OctoPlus to develop Theratechnologies's glucagon-like peptide-1 series    "/></Deals><PatentFamilies><PatentFamily id="652760" number="WO-2005117830" title="Liquid depot formulations"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Solasia Pharma KK" id="1034811"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="R-Pharm" id="1059001"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Braeburn Pharmaceuticals Inc" id="1076423"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GS Development AB" id="23771"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>